Neuraxis, Inc. (NRXS) vs Rani Therapeutics Holdings, Inc. (RANI)

Neuraxis, Inc. and Rani Therapeutics Holdings, Inc. are both Biotechnology companies. Neuraxis, Inc. and Rani Therapeutics Holdings, Inc. are of similar size ($97.2M and $94.8M). Rani Therapeutics Holdings, Inc. grew revenue faster over the last twelve months: 78.7% against 65.2%. Neuraxis, Inc. has the higher net margin (−159.0% vs −597.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Neuraxis, Inc. leads on 9 and Rani Therapeutics Holdings, Inc. on 6.

Valuation

Metric NRXS RANI Biotechnology median
P/E n/m n/m 8.50
P/S 17.55 23.73 9.71
P/B 13.86 2.50 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 16.00 16.27 9.21
Earnings yield (10.13%) (42.19%) (33.15%)
Free cash flow yield (6.20%) (16.98%) (25.50%)

Profitability

Metric NRXS RANI Biotechnology median
Gross margin 85.56% 100.00% 65.16%
Operating margin (144.51%) (652.78%) 0.00%
Net margin (159.01%) (596.97%) 0.00%
Free cash flow margin (106.10%) (402.83%) 0.00%
Return on equity (153.96%) (155.24%) (56.36%)
Return on assets (98.96%) (77.54%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NRXS RANI Biotechnology median
Revenue growth (TTM) 65.22% 78.73% 6.02%
EPS growth (last fiscal year) 22.13% 57.14% 30.26%
Revenue growth, 5-year CAGR 13.08% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NRXS RANI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.04 5.31 4.72
Net debt to EBITDA 0.64 1.33 0.96

Dividend

Metric NRXS RANI Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric NRXS RANI Biotechnology median
Market cap 97.19m 94.79m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack